Intuitive Surgical, Inc. (ISRG): what the price assumes

In the published model solve dated 2026-Q2, anchored at $373.80, Intuitive Surgical, Inc. (ISRG) is priced for today's economics sustained for ~11.3 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. Narrative composed 2026-07-24.

Generated: 2026-08-30 · Source: https://boothcheck.com/report/ISRG

Headline

What The Price Assumes (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

The operating-margin figure is value-band context at year 8: derived from the framework's value band, a separate calculation — not part of the priced-in solve.

Solve inputs: computed at a 11.2% cost of capital; growth searched up to the 25% self-funding ceiling.

How unusual the bet is: elevated (limited comparison data)

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=18)

Economic-Unit Decomposition (Sum Of The Parts)

Only one reportable economic unit is present in the current topology source. Consolidated operating lenses remain available, but there is no multi-unit decomposition.

No total common-equity value is stated. One or more material units lack a supported unit value. The displayed values are an indicative subtotal; consolidated debt and cash cannot be applied to a fraction of the company.

Solvency

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• This is a toll on operations rather than a machinery business: 85% of second-quarter revenue was recurring, with instruments and accessories bringing in $1.73 billion against $685 million of system sales.

• The specific risk is duration rather than level, because today's economics have to hold for about 12 years to account for the price, a stretch only a small minority of fast-growing companies have managed for even a decade.

• The next read is the October quarter, where the question is whether da Vinci procedure growth lands near the midpoint of the maintained 13.5% to 15.5% full-year range after growing about 15% in the second quarter.

Bull Case

Intuitive does not really sell robots. It sells a per-operation toll. Each da Vinci procedure consumes instruments with a fixed number of uses in them, each installed system carries a service contract, and the result is that 85% of second-quarter revenue repeated without anyone having to close a new capital sale. Instruments and accessories brought in $1.73 billion in the quarter, up 18%, against $685 million of systems revenue and $472 million of services.

The installed base is therefore the asset, and it is compounding. Intuitive finished June with 11,710 da Vinci systems in the field, 12% more than a year earlier, having placed 468 in the quarter against 395 in the same quarter of 2025. A placement is not a sale so much as the opening of an account. It generates instrument revenue for as long as the hospital operates, and it grows as that hospital's surgeons work through their own adoption curve.

The curve is steepening rather than flattening. Worldwide procedures across da Vinci and Ion grew about 16% in the quarter, with da Vinci procedures up about 15% and Ion procedures up about 36%; the Ion installed base reached 1,096 systems, 21% higher than a year earlier. Ion matters because it opens lung biopsy, a procedure category the da Vinci franchise never touched.

Operating leverage is doing what it is supposed to do. Revenue rose 19% to $2.89 billion while operating income under GAAP climbed 31% to $972 million, a GAAP operating margin of 33.6% on a GAAP gross margin of 67.8%, up from 66.3% a year earlier; diluted earnings came to $2.29 a share, 26% higher. Revenue growing at 19% and profit at 31% is the arithmetic of a business whose next unit of volume costs less to serve than the last one.

The upgrade cycle is a second annuity layered on the first. Of the 468 systems placed in the quarter, 246 were da Vinci 5. Same customer, newer platform, fresh service agreement, and an instrument set that carries forward.

Competition is genuinely arriving and the bull case should say so. Medtronic's Hugo system cleared the FDA for urologic procedures in December 2025 and the company filed to expand it into general and gynecologic surgery in June 2026. The counter is not that the technology is unmatchable. It is that the switching cost sits in surgeon training hours and hospital instrument inventory rather than in the robot itself, and Intuitive already has 11,710 systems embedded in operating rooms with staff credentialed on them.

The balance sheet removes the interesting failure modes entirely. There is no debt, and $8.63 billion of cash, equivalents and investments sat on the books at quarter end. This company funds its factories, its hospital financing programmes and its research out of its own cash flow, which is a rare position for a business still growing at this rate.

Bear Case

At about 39 times the operating profit the business produced over the trailing year, the argument stops being about whether Intuitive is a good company and becomes a question about how long it stays this good. Today's economics have to hold for about 12 years to account for the price. Of companies that have grown at comparable rates, only around 14% held the pace for even a decade. The multiple itself sits at the very top of its peer distribution, well past the upper quartile of medical device names.

What makes this bear case awkward, and worth stating plainly, is that the profitability demand is easy. The price works against an operating margin of about 22%; the company already earns about 29.5%. Nothing has to improve. The entire wager is on persistence, and persistence is the one thing a company cannot demonstrate in advance.

The second quarter showed exactly where that wager gets tested. Revenue grew 19% and procedures about 16%, but management left full-year da Vinci procedure growth guidance at 13.5% to 15.5% and said it expects to land near the midpoint, which is below the pace the quarter just delivered; the shares fell roughly 10% on the news. A stock that drops on a 19% revenue quarter is telling you what it is priced for. There is no room in this multiple for deceleration, only for continuation.

Competition has changed character. For two decades the practical alternative to a da Vinci was an open or laparoscopic procedure. Medtronic's Hugo now has US clearance for urologic surgery, granted in December 2025, and Medtronic filed in June 2026 to extend it into general and gynecologic procedures, the categories where the bulk of robotic volume actually sits. Johnson and Johnson is working toward a submission for its own system. None of these has to take meaningful share to matter. A credible second bidder changes what a hospital pays for a system and what it accepts on an instrument contract, and pricing power is a larger part of this company's economics than volume is.

There is a cost line moving the wrong way too. Full-year non-GAAP gross profit margin guidance of 68% to 69% includes roughly one percentage point of tariff impact. That is a charge on a global manufacturing footprint that the company does not control and cannot engineer away quickly.

Systems revenue is the other exposed line. It is a hospital capital budget item, and capital budgets are the first thing a health system defers when reimbursement or volumes wobble. Procedures are stickier than placements, but placements are what feed the future procedure base.

Solvency offers no comfort here, which is a strange thing to write about a company with no debt. There is no scenario in which this business fails financially. But $8.63 billion of cash and investments is a small fraction of what the market is paying for the enterprise, and a balance sheet cannot catch a multiple. If the growth rate settles into the low teens rather than the high teens, the repricing happens in the multiple, and the cash sits there while it does.

Valuation

At $338.38, the market is paying about 39 times the operating profit this business generated over the trailing year. The more useful way to hold that number is as a statement about time: at this price, today's economics need to hold for about 12 years before the arithmetic reconciles.

Notably, the demand is not for better profitability. Run the same exercise on the operating line and the price works against a margin of about 22%, while the company currently earns about 29.5%. There is slack there, not stretch. Everything the price is asking for lives in the duration of the growth rather than in the quality of it, and that is a different kind of bet, harder to falsify quarter to quarter and correspondingly slower to correct.

Across valuation approaches, only one family reaches the price at all. The price sits at about 3.57 times where the asset-value approaches land, about 3.8 times where the earnings-power methods land, and about 1.97 times where peer multiples put it. Only the forward-growth methods get near. That pattern is not a modelling failure; it describes what these lenses can and cannot see. Book value and capitalised trailing earnings measure what a company has accumulated and what it currently earns. Neither of them can price an installed base of 11,710 machines that generates instrument and service revenue every year without a new sale being made. The premium above those lenses is what the market pays for that annuity continuing to widen.

Within its cohort the multiple sits at the very top of the peer distribution, well beyond the upper quartile of comparable device makers. The defence of that position is composition rather than growth alone: 85% of revenue recurred last quarter, and recurring revenue at that share carries a different risk profile from a device maker dependent on winning the next hospital tender.

The balance sheet is the simplest part of the picture and also the least decisive. There is no debt at all, $8.63 billion of cash, equivalents and investments sits on the books, and the share count has drifted down about 0.5% a year. What that buys is the removal of every financing risk from the analysis. What it does not buy is protection from a change of mind about how long the growth lasts, and at this multiple that is where nearly all the variance lives.

Catalysts

The second-quarter release on July 16, 2026 reset the near-term debate. Revenue of $2.89 billion grew 19%, worldwide procedures grew about 16%, and 468 da Vinci systems were placed against 395 a year earlier, of which 246 were the newer da Vinci 5. What moved the stock was not any of that. Management held full-year da Vinci procedure growth guidance at 13.5% to 15.5% and pointed to the midpoint, and the shares fell about 10%. The October quarter is the next scheduled test of whether that guide was conservatism or observation.

Margins carry the second thread. Non-GAAP gross profit margin guidance for the year was raised to 68% to 69% of revenue and includes roughly one percentage point of tariff cost, with non-GAAP operating expense growth guided to 11% to 13%. The tariff line is the one to watch because it is external, and the expense line is the one to watch because it is the company's own choice about how hard to invest while growth is available.

The competitive calendar is the third and the slowest-moving. Medtronic's Hugo system was cleared in the United States for urologic procedures in December 2025, and Medtronic filed in June 2026 to expand it into general and gynecologic surgery, which is where the volume is. Johnson and Johnson continues to work toward a submission for its own platform. Regulatory clearances do not move procedure share quickly, but they change the negotiating position of every hospital buying its next system, and that shows up in pricing long before it shows up in installed base.

Peer Cohorts (Per Segment, With Filing Citations)

Surgical systems (single segment) (reported)

• GMED (GLOBUS MEDICAL, INC.)
• FY2025 10-K: …in sufficient quantities so that products are available when needed for surgical procedures. Safety stock levels are determined based on a number of factors, including demand, manufacturing lead times, and quantities required to maintain service levels. Surgical Instrument, Implant Sets and Equipment Sales For many…
• FY2025 10-K: 0.001 par value per share, was cancelled and converted into the right to receive cash in an amount equal to $5.85 per share of common stock of Nevro, without interest and subject to any applicable withholding taxes. Product & Service Categories While we group our revenue into two categories, Musculoskeletal Solutions…
• BSX (BOSTON SCIENTIFIC CORP)
• FY2025 10-K: …and restructuring-related net charges (credits), certain litigation-related net charges (credits) and EU MDR implementation costs ( 1,102 ) Amortization expense ( 897 ) Operating income (loss) 3,613 Other income (expense), net ( 228 ) Income (loss) before income taxes $ 3,385 105 Year Ended December 31, 2024 MedSurg…
• FY2025 10-K: …pseudocysts (AXIOS™ Stents and Electrocautery Enhanced Delivery Systems), single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system (SpyGlass™), and in endoscopic retrograde cholangiopancreatography (ERCP) procedures (EXALT™ Model D Single-Use Duodenoscopes), our portfolio of…
• SYK (STRYKER CORP)
• FY2025 10-K: …technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Our products include surgical equipment and surgical navigation systems; endoscopic and…
• FY2025 10-K: …as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors. Products and services are primarily transferred to customers at a point in time, with some transfers of services taking place over time. In 2025 less than 10 % of our sales were…
• MDT (Medtronic plc)
• FY2025 10-K: …for pulse oximetry, capnography, level of consciousness and cerebral oximetry. Medical Surgical's net sales for fiscal year 2025 were $8.4 billion, flat as compared to fiscal year 2024, with performance outlined below. 36 Table of Content The charts below illustrate the percent of Medical Surgical net sales by…
• FY2025 10-K: …stapling and energy platform. • Our ability to execute ongoing strategies addressing the pressures to bariatric surgery procedure volumes in the U.S. from pharmaceuticals, and growth of surgical soft tissue robotics procedures in the U.S. • Our ability to create markets and drive products and procedures into emerging…
• EW (EDWARDS LIFESCIENCES CORPORATION)
• FY2025 10-K: …product innovation, robust and expanding clinical evidence to support approvals and adoption, as well as comprehensive support to ensure excellent real-world patient outcomes. Sales of our TMTT products represented 9%, 7%, and 4% of our net sales in 2025, 2024, and 2023, respectively. Surgical Structural Heart We…
• FY2025 10-K: …We have in the past and are continuing to experience constrained procedure volumes and sales for our products because more products, including Edwards' own products, are competing for the same facilities and staffing within hospitals. See " Competition" under " Business" in Part I, Item 1 included herein. The success…
• TFX (TELEFLEX INCORPORATED)
• FY2025 10-K: …is permitted. We are currently evaluating this guidance to determine its impact on our consolidated financial statements. In September 2025, the FASB issued new guidance designed to clarify and modernize the accounting for costs related to internal-use software. The updated guidance is intended to provide enhanced…
• FY2025 10-K: …name. Interventional: Our Interventional product category offers devices that facilitate a variety of applications to diagnose and deliver treatment of coronary and peripheral vascular disease. These products primarily consist of a diverse portfolio of coronary catheters, structural heart support devices and…
• DXCM (DEXCOM, INC.)
• FY2025 10-K: …In the future, we plan to expand our product offering to people who are pregnant and cleared/approved indications to address people with pre-diabetes, people who are obese, and people in the hospital setting. Although the majority of our revenue has been generated in the United States, we have expanded our operations…
• FY2025 10-K: …diabetes research are continually seeking ways to prevent, cure or improve treatment of diabetes. Therefore, our products may be rendered obsolete by technological breakthroughs in diabetes monitoring, treatment, prevention or cure. In selling our G6, G7, G7 15 Day, Dexcom One and Dexcom ONE+, we compete directly…
• PODD (INSULET CORPORATION)
• FY2025 10-K: …funds with a limited number of financial institutions that have a high investment grade credit rating. See Notes 4 and 5 for customer concentration. Supply Risk- The Company uses different types of semiconductor chips, which are sourced from external suppliers, in the manufacturing of its products. While the Company…
• FY2025 10-K: …Omnipod ® 5 and its predecessors Omnipod DASH and Classic Omnipod. Each product features a small, lightweight, self-adhesive disposable tubeless Omnipod device ("Pod") that the user fills with insulin and wears directly on the body for up to three days at a time, which delivers personalized doses of insulin and…

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Economic-unit decomposition (SOTP): each disclosed business unit is assigned its native valuation basis before any multiple is applied. Operating units are valued on enterprise value; funded financial units are valued on their own common equity, because their borrowings fund earning assets rather than levering the parent. A company total is stated only once every material unit carries a supported value and the parent capital bridge reconciles.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.